Products
Pre-made Uliledlimab benchmark antibody ( Whole mAb, anti-NT5E/CD73 therapeutic antibody, Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-599
Pre-Made Uliledlimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Uliledlimab is a CD73 (5-Nucleotidase) targeting humanised monoclonal antibody, being developed I-Mab Biopharma, for the treatment of various cancers, including solid tumours.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-599-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Uliledlimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody |
| INN Name | Uliledlimab |
| Target | CD73 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | TRACON Pharmaceuticals;I-Mab Biopharma |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Development Tech | na |
<